CN1698838A - Chinese medicine for treating cardiovascular disease and method for preparing same - Google Patents
Chinese medicine for treating cardiovascular disease and method for preparing same Download PDFInfo
- Publication number
- CN1698838A CN1698838A CN 200510077487 CN200510077487A CN1698838A CN 1698838 A CN1698838 A CN 1698838A CN 200510077487 CN200510077487 CN 200510077487 CN 200510077487 A CN200510077487 A CN 200510077487A CN 1698838 A CN1698838 A CN 1698838A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicinal liquid
- tablet
- cardiovascular disease
- hour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a Chinese medicament for treating cardiovascular diseases and its preparing process, which comprises the following constituents (by weight portions), astragalus root 1000-2000, rhizome of Sichuan lovage 500-1000, kuh-seng 500-1000.
Description
Technical field
The present invention relates to a kind of Chinese medicine and preparation technology thereof, this Chinese medicine has benefiting QI for activating blood circulation, promoting QI circulation for relieving depression, and the function that coronary circulation-promoting pain-relieving, consolidating YIN are throbbed with fear surely is used for cardiovascular disease such as blood stasis-type thoracic obstruction caused by qi deficiency, cardiopalmus, coronary heart disease, angina pectoris, arrhythmia.
Background technology
The sickness rate that coronary heart disease, angina pectoris, myocardial ischemia merge cardiovascular disease such as arrhythmia is increasing year by year, first of its case fatality rate row various diseases, and the serious threat mankind's life and health.Present clinical main applied chemistry Drug therapy, determined curative effect, safe and reliable Chinese medicine preparation seldom have the significant social economic implications so research and develop this apoplexy due to endogenous wind medical instrument.
Angina pectoris is feature with the chest pain, belongs to the traditional Chinese medical science " thoracic obstruction " category.Thoracic obstruction person, QI and blood is inaccessible also obstructed in the heart, stagnation of QI and blood may bring about pain.A large amount of clinical datas show, thoracic obstruction person often with chest pain companion cardiopalmus, breathe hard, uncomfortable in chest, spontaneous perspiration, work postemphasis etc. are characteristics.Pulse condition sees that a left side is very little faint more, and the fat dark and gloomy person of pale tongue accounts for significant proportion.Analyse its etiology and pathogenesis, surely belong to QI-deficiency of the heart and lung, fortune blood is unable, thus the gradually hyperamization stasis of blood and passages through which vital energy circulates impatency chest obstruction with pain; The motive is irregular then pained and throb with fear.Control suitable benefiting QI for activating blood circulation, promoting QI circulation for relieving depression, coronary circulation-promoting pain-relieving, consolidating YIN is throbbed with fear surely.
Do not retrieve the medicine that cardiovascular disease pathogenesis such as coronary heart disease, angina pectoris, arrhythmia are had good therapeutic effect and have no side effect in the prior art.
Summary of the invention
The object of the present invention is to provide a kind ofly has good therapeutic effect and does not have the Chinese medicine and the preparation technology thereof of obvious toxic-side effects above-mentioned cardiovascular disease.
For achieving the above object, the present invention adopts following technical scheme: it is made up of the component of following parts by weight:
The Radix Astragali 1000～2000 Rhizoma Chuanxiongs 500～1000 Radix Sophorae Flavescentiss 500～1000
The preparation technology of Chinese medicine of the present invention is: the Radix Astragali, Rhizoma Chuanxiong, Radix Sophorae Flavescentis are used ethanol extraction twice respectively, and each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction, filter, filtrate and above-mentioned medicinal liquid merge, and being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), add right amount of auxiliary materials, mixing, granulate, drying promptly gets granule, adopt common process, it can further make tablet, dispersible tablet, buccal tablet, oral cavity disintegration tablet, effervescent tablet, pill, drop pill, capsule, oral liquid, mixture, syrup etc.
The sweet temperature of the Radix Astragali in the side, the function benefiting qi and raising yang, strengthening superficial resistance to stop perspiration, the gas of high reinforcing the heart lung, promotion blood is monarch.The Rhizoma Chuanxiong property and flavor of peppery and warm, the function blood circulation promoting and blood stasis dispelling, activating QI to alleviate the depression, coronary circulation-promoting pain-relieving are minister.5 invigorating middle warmer of two medicines phase have logical, and logical middle residence is mended, and finishes benefiting QI for activating blood circulation jointly, and the function of coronary circulation-promoting pain-relieving is so be applicable to " blood stasis-type thoracic obstruction caused by qi deficiency ".Radix Sophorae Flavescentis bitter in the mouth cold nature.Bitter energy consolidating YIN is in case the dissipation of the suffering temperature of stilbene, rhizome of chuanxiong is Kidney-Yin; Tremble with fear and to remove asthenic fire in the heart, in case the unlikely asthenic fire that causes of the temperature compensation of stilbene, rhizome of chuanxiong is secretly given birth to." Mingyi Bielu " cloud: Radix Sophorae Flavescentis can " the sedate benefit be smart for nourishing the liver courage, settling five organs, and sharp nine orifices removes latent heat etc." " Amplification on Materia Medica benefit " also cloud " Radix Sophorae Flavescentis can high nourishing YIN gas, or the like.Thereby " Radix Sophorae Flavescentis play protect cloudy nourishing blood to tranquillize the mind throb with fear surely act as the assistant make.
It is clear and definite to take a broad view of three medicine effects, and Each performs its own functions, and compatibility is rigorous, plays benefiting QI for activating blood circulation altogether, promoting QI circulation for relieving depression, and the merit that coronary circulation-promoting pain-relieving, consolidating YIN are throbbed with fear surely is so should be used for cardiovascular disease such as blood stasis-type thoracic obstruction caused by qi deficiency, cardiopalmus, coronary heart disease, angina pectoris and arrhythmia.
Chinese crude drug of the present invention is the kind that Chinese Pharmacopoeia records.Pharmacodynamic study is the result show, Chinese medicine of the present invention can make the blood pressure drops of normal anesthetized dog, decreased heart rate, and myocardial contraction slows down, and can reduce coronary resistance, increases coronary flow, reduces myocardial oxygen consumption.The rat heart muscle ischemia that the ligation coronary artery is caused has significant protective effect, can reduce the heart necrosis area, reduces CK and FFA in the blood.The rat ischemia arrhythmia that the ligation coronary artery is caused has tangible antagonism, can reduce incidence of arrhythmia, shortens chamber speed time-histories, the generation of quivering in the chamber of preventing.Simultaneously, rat aconitine arrhythmia is also had obvious antagonism, the time of occurrence that can obviously prolong chamber morning, chamber speed, chamber is quivered reduces the incidence rate of asystole.
The acute toxicity tests shows, behind ig. of mice Chinese medicine 50g/kg of the present invention, outward appearance, the behavior of not seeing mice has any unusual, more do not have dead generation, and the maximum tolerated dose of mice is 150g/kg, is equivalent to 143 times (cumulants) of clinical consumption.Long term toxicity test is the result show, dosage continuous irrigation stomach with 56.7～226.8g crude drug/kg (be equivalent to clinical consumption 10～40 times) is given 12 weeks of Chinese medicine of the present invention, during the administration and after 2 weeks of drug withdrawal, each organizes all no abnormal change of mode of appearance, behavior sign of rat, and the body weight gain situation is normal.The biochemical indicator of hemogram, hepatic and renal function and main organs histopathologic examination there is no unusually, and the major organs histological examination does not find that pathologic changes.
Clinical research is the result show, Chinese medicine of the present invention is 90.9% to anginal total effective rate, and centering, severe curative effect to treat angina pectoris are more obvious, and effective percentage reaches 100%.Recover operate as normal person after the treatment in various degree and account for 75.76%.The electrocardiogram effective percentage is 69.0%.Serum total cholesterol, triglyceride and beta lipoprotein rising person also all there is significant curative effect, respectively average decline 30.62mg%, 35.56mg% and 61.95mg%.Significant difference (p all＜0.05) is all arranged.Find in the research that Chinese medicine of the present invention also has obvious curative effects to the ventricular premature contraction that takes place frequently, artrial premature beat, atrial fibrillation and supraventricular tachycardia etc.Treatment pastoral area patients with coronary heart disease 86 examples, it is 70.21% to anginal effective percentage, is 71.25% to the improvement rate of cardiopalmus, to breathing hard and dyspneic effective percentage is 72.13%.Obvious effective rate and total effective rate to 41 routine ischemic ECG change patients reach 58.54% and 70.73% respectively.The companion chamber of taking place frequently 6 examples morning in 41 examples, room 1 example early that takes place frequently, all effectively.
Research also finds, Chinese medicine of the present invention all apparently higher than inclined to one side deficiency of YIN person, and is observed the trend of the further raising curative effect that extends the period of treatment to inclined to one side deficiency of vital energy person's clinical disease curative effect and ECG curative effect.
2 months to be 1 course of treatment short term effect of 40 routine patients with arrhythmia is carried out clinical observation on the therapeutic effect with Chinese medicine of the present invention.The chamber of taking place frequently 21 examples morning among this group patient, room 8 examples early that take place frequently, atrial fibrillation 4 examples, chamber cross-connecting area premature beat 2 examples take place frequently; Other has II ° of I type and II ° of each 1 example of II type atrioventricular block person.Routine chambers 21, treatment back produce effects 9 examples in morning, effective 6 examples, its obvious effective rate and total effective rate are respectively 42.9% and 71.4%.Produce effects 7 examples (accounting for 87.5%) in room 8 examples morning that take place frequently, effective 1 example, 8 examples are all effectively.Produce effects 1 example in atrial fibrillation 4 examples, effective 2 examples.Produce effects and effective each 1 example in chamber cross-connecting area premature beat 2 examples that take place frequently.In addition, II ° of I type atrioventricular block 1 example, concurrent supraventricular tachycardia 1 example of heart infarction, all produce effects.The parallel rhythm and pace of moving things 1 example effectively.All the other cases are invalid.In sum, produce effects 20 examples account for 50.0% in 40 examples, and effective 11 examples account for 27.5%, and total effective rate is 77.5%.As can be seen, Chinese medicine of the present invention is evident in efficacy to rapidity and ectopic cardiac arrhythmia.
From the relation analysis of traditional Chinese medical science typing and curative effect, clear and definite traditional Chinese medical science typing person 35 examples are arranged in 40 examples, wherein inclined to one side qi-deficiency type 26 examples, effective 24 examples, effective percentage is 92.3%; Inclined to one side deficiency of YIN person's 9 examples, effective 5 examples account for 55.6%.Significant difference (p＜0.05) is arranged between two groups of effective percentage.The arrhythmia patient who points out Chinese medicine of the present invention should be mainly used in based on the deficiency of vital energy is advisable.
Use treatment by Chinese herbs coronary heart disease with qi deficiency and blood stasis of the present invention (148 example), and contrast with BUXINQI KOUFUYE (120 example), the obvious effective rate of Chinese medicine of the present invention and total effective rate are respectively 62.2% and 91.9% as a result, and BUXINQI KOUFUYE is respectively 43.3% and 79.2%.The curative effect of Chinese medicine of the present invention is apparently higher than contrast medicine (p＜0.05).Improve angina pectoris, uncomfortable in chest, breathe hard and clinical symptoms such as cardiopalmus aspect, Chinese medicine of the present invention also obviously is better than contrasting medicine.The Electrocardiographic obvious effective rate of ischemia type Chinese medicine of the present invention (50.1%) also is higher than contrast medicine (36.2%).Chinese medicine of the present invention to coronary heart disease with qi deficiency and blood stasis common symptoms such as angina pectoris, uncomfortable in chest, breathe hard and the obvious effective rate of cardiopalmus and total effective rate all apparently higher than BUXINQI KOUFUYE (p＜0.05).
Detect through resting electrocardiogram and ambulatory electrocardiogram, ischemia type electrocardiogram improver 141 examples, BUXINQI KOUFUYE group 116 examples appear in treatment by Chinese herbs group of the present invention.The electrocardiogram obvious effective rate of treatment back treatment by Chinese herbs group of the present invention is 50.1%, and matched group is 36.2%, and the total effective rate of treatment by Chinese herbs group of the present invention is 69.5%, and matched group is 65.5%.
The specific embodiment
Embodiment 1
Get Radix Astragali 1500g, Rhizoma Chuanxiong 750g, Radix Sophorae Flavescentis 750g, use ethanol extraction twice respectively, each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction filtered, and filtrate and above-mentioned medicinal liquid merge, being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), adds right amount of auxiliary materials such as dextrin, and mixing is granulated, drying is made 1000g, and packing promptly gets granule.
Embodiment 2
Get Radix Astragali 1200g, Rhizoma Chuanxiong 600g, Radix Sophorae Flavescentis 600g, use ethanol extraction twice respectively, each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, each 1～2 hour, collecting decoction filtered, filtrate and above-mentioned medicinal liquid merge, being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), adds right amount of auxiliary materials such as dextrin, mixing, granulate, drying adopts common process, can be made into tablet, dispersible tablet, buccal tablet, effervescent tablet.
Embodiment 3
Get Radix Astragali 1000g, Rhizoma Chuanxiong 500g, Radix Sophorae Flavescentis 500g, use ethanol extraction twice respectively, each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction filtered, filtrate and above-mentioned medicinal liquid merge, and being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), add right amount of auxiliary materials such as dextrin, mixing, granulate, drying adopts common process, and capsule is made in fill.
Embodiment 4
Get Radix Astragali 2000g, Rhizoma Chuanxiong 1000g, Radix Sophorae Flavescentis 1000g, use ethanol extraction twice respectively, each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction filtered, and filtrate and above-mentioned medicinal liquid merge, and being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), adds right amount of auxiliary materials, adopts common process, makes pill.
Embodiment 5
Get Radix Astragali 1800g, Rhizoma Chuanxiong 900g, Radix Sophorae Flavescentis 900g, use ethanol extraction twice respectively, each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction filtered, and filtrate and above-mentioned medicinal liquid merge, and being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), adds right amount of auxiliary materials, adopts common process, makes oral liquid.
Embodiment 6
Get Radix Astragali 1600g, Rhizoma Chuanxiong 800g, Radix Sophorae Flavescentis 800g, use ethanol extraction twice respectively, each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction filtered, and filtrate and above-mentioned medicinal liquid merge, and being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), adds adjuvants such as simple syrup, adopts common process, makes syrup.
Embodiment 7
Get Radix Astragali 1400g, Rhizoma Chuanxiong 700g, Radix Sophorae Flavescentis 700g, use ethanol extraction twice respectively, each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid, and is standby; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction filtered, and filtrate and above-mentioned medicinal liquid merge, and being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), adds adjuvant, stand at low temperature, and the cold preservation after-filtration is made mixture.
Claims (3)
1. the Chinese medicine that is used for cardiovascular disease, form by the component of following parts by weight:
The Radix Astragali 1000～2000, Rhizoma Chuanxiong 500～1000, Radix Sophorae Flavescentis 500～1000.
2. the described Chinese medicine that is used for cardiovascular disease of claim 1, it is characterized in that: it can be granule, tablet, dispersible tablet, oral cavity disintegration tablet, buccal tablet, effervescent tablet, pill, drop pill, capsule, oral liquid, mixture, syrup etc.
3. the described preparation technology who is used for the Chinese medicine of cardiovascular disease of claim 1, its spy is: the Radix Astragali, Rhizoma Chuanxiong, Radix Sophorae Flavescentis are used ethanol extraction twice respectively, and each 1～2 hour, merge medicinal liquid, filter, filtrate recycling ethanol gets medicinal liquid; Medicinal residues decoct with water twice, and each 1～2 hour, collecting decoction filtered, and filtrate and above-mentioned medicinal liquid merge, and being concentrated into relative density is the clear paste of 1.20～1.40 (60 ℃), adds right amount of auxiliary materials, mixing, and technology is made the described preparation of claim 2 routinely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100774874A CN100493527C (en) | 2005-06-24 | 2005-06-24 | Chinese medicine for treating cardiovascular disease and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100774874A CN100493527C (en) | 2005-06-24 | 2005-06-24 | Chinese medicine for treating cardiovascular disease and method for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698838A true CN1698838A (en) | 2005-11-23 |
| CN100493527C CN100493527C (en) | 2009-06-03 |
Family
ID=35475192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100774874A Expired - Fee Related CN100493527C (en) | 2005-06-24 | 2005-06-24 | Chinese medicine for treating cardiovascular disease and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100493527C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101716220B (en) * | 2009-11-20 | 2012-07-04 | 杭州平和安康医药科技有限公司 | Shielding alkaloid traditional Chinese medicine |
| CN102600422A (en) * | 2011-11-28 | 2012-07-25 | 王国荣 | Traditional Chinese mixture for treating angina pectoris at catabatic period |
| CN103301278A (en) * | 2013-04-16 | 2013-09-18 | 武汉珈创生物技术有限公司 | Traditional Chinese medicine preparation and application thereof |
-
2005
- 2005-06-24 CN CNB2005100774874A patent/CN100493527C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101716220B (en) * | 2009-11-20 | 2012-07-04 | 杭州平和安康医药科技有限公司 | Shielding alkaloid traditional Chinese medicine |
| CN102600422A (en) * | 2011-11-28 | 2012-07-25 | 王国荣 | Traditional Chinese mixture for treating angina pectoris at catabatic period |
| CN103301278A (en) * | 2013-04-16 | 2013-09-18 | 武汉珈创生物技术有限公司 | Traditional Chinese medicine preparation and application thereof |
| CN103301278B (en) * | 2013-04-16 | 2014-11-05 | 武汉珈创生物技术有限公司 | Traditional Chinese medicine preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100493527C (en) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100493527C (en) | Chinese medicine for treating cardiovascular disease and method for preparing same | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN1939483A (en) | Heart-nourishing capsules for treating coronary heart disease | |
| CN101342207B (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia, hyperlipemia and preparation method thereof | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1215853C (en) | Traditional Chinese medicine for curing arrhythmia and its preparation | |
| CN100536890C (en) | Traditional Chinese medicine composition for preventing arrhythmia and processes for producing same | |
| CN1839934A (en) | Chinese traditional medicine and its preparation method and use | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN101721638B (en) | Oral liquor for treating coronary heart disease | |
| CN1686242A (en) | Composition possessing therapeutic effect for high blood fat and heart brain blood vessel diseases | |
| CN105535890B (en) | A kind of pharmaceutical composition and preparation method thereof for treating cardiovascular disease | |
| CN100339091C (en) | Preparation of pharmaceutical composition for treating coronary heart disease and angina pectoris and preparation method thereof | |
| CN115429836B (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN102228596A (en) | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris | |
| CN101342208A (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia and preparation method thereof | |
| CN101632728B (en) | Application of Chinese medicinal composition in preparing medicament for protecting blood brain barrier | |
| CN101658568B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary heart disease | |
| CN101590178B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating refractory premature beat of elderly patient | |
| CN104147423A (en) | Decoction for treating hand and foot numbness after stroke | |
| CN101279045B (en) | Medicament for curing arrhythmia and method of preparing the same | |
| CN1442186A (en) | Medicine for treating coronary disease and its preparation method | |
| CN103479712B (en) | Traditional Chinese medicine composition for treating coronary heart disease angina and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Yin Cuan Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090603 Termination date: 20170624 |